Barclays Rates Corteva (CTVA) buy, $91 Price Target

Barclays has reiterated its buy rating on Corteva, Inc. with a price target of $91, reflecting its confidence amid mixed analyst opinions, a 20.20% upside from the current price.

By EarningsIQ Research Desk · Published Jun 12, 2026, 9:13 PM EDT · Updated Jun 16, 2026, 12:02 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Barclays rated Corteva, Inc. ($CTVA) "buy" with a $91 price target on June 11, 2026.

Since the rating, $CTVA is up 5.0% after 1 week, up 15.0% after 1 month and up 14.9% to date (from the $11.21 close on Jun 11, 2026).

CTVA Corteva, Inc.

$12.88 +27.52% year to date

Daily close · Oct 16, 2026

Key Points

On June 11, 2026, Barclays reaffirmed its buy rating for Corteva, Inc. (CTVA), setting a price target of $91 while the stock trades at $75.71.
Barclays's $91 price target implies 20.20% upside from Corteva, Inc.'s ($CTVA) current $75.71 share price.
Corteva's stock has faced volatility, trading between a 52-week low of $60.54 and a high of $90.97, which reflects investor uncertainty.
Corteva, a leader in agricultural inputs, reported revenue of $17.81 billion for the last year, but its revenue growth is slightly down at -1.2%.

Get $CTVA trade alerts by text

We text you when insiders, Congress or big funds trade $CTVA. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Corteva, Inc. alert may contain errors. Disclosures

Barclays Sticks with Buy Rating on Corteva

On June 11, 2026, Barclays reiterated its buy rating on Corteva, Inc. (CTVA) with a price target of $91. The stock is currently trading at $75.71, indicating that analysts see potential upside from current levels. This move reflects Barclays' ongoing confidence in the company's future despite market fluctuations.

Analysts Set New Price Targets

Barclays' rating comes amid a variety of opinions from Wall Street. For instance, UBS has maintained a Neutral rating with a target of $15.00, which is well below Corteva's current trading price. Recently, JP Morgan upgraded its rating to Overweight and set a target of $19.00, up from $83.00. Meanwhile, Keybanc also upgraded its rating to Overweight with a target of $17.00. Other firms like Citigroup and BMO Capital have maintained their Neutral and Outperform ratings, respectively, with price targets around $91.00 and $95.00. This diverse range of opinions shows differing views on Corteva's performance and potential.

Stock Performance Context

Corteva's stock is currently priced at $75.71, which is significantly below its 52-week high of $90.97. The stock has experienced a downturn, trading near its 50-day moving average of $82.94. This context is important as analysts weigh their ratings; while Barclays remains optimistic, other analysts are more cautious.

12-month forecast

$CTVA price target

Corteva, Inc. daily closes and this analyst's $91 target. Not advice.

Recent Earnings

Corteva reported revenue of $17.81 billion, but its revenue growth has declined by 1.2%, signaling some challenges in the agricultural sector. The company's earnings per share (EPS) stands at $1.65, and it has a net margin of 5.7%. Investors will be looking for signs of recovery when Corteva announces its next earnings on November 3, 2026.

Earnings drift grade

Outlook vs expectations on the last report — not price action.

B+ 82/100

Reported May 5, 2026

Forward outlook
3 analysts raised price targets.
EPS & revenue
EPS beat estimates by 25.4%. Revenue beat estimates by 3.6%.
Profit surprise
EBITDA beat by 13 percent. Operating income beat by 9 percent.
Pre-earnings setup
Expectations were about average.
Analyst signal
3 target raises.
Earnings quality
Gross margin up 1.5 points. Operating margin up 4.9 points. Positive free cash flow.

Earnings Call Summary

Corteva had a strong first quarter with organic sales up 7 percent, driven by seed volume growth of 6 percent and crop protection gains across all regions. Operating EBITDA jumped 21 percent year over year to over $1.4 billion, with margin expansion of 240 basis points coming from price gains, cost savings, and favorable currency effects. Management highlighted that net royalty expense fell another $30 million as the seed business moves toward royalty positive status later this year, particularly from licensing deals like Enlist soybeans in Brazil.

Guidance The company reaffirmed full-year operating EBITDA guidance of $4 billion to $4.2 billion with earnings per share of $3.45 to $3.70. Management expects continued volume growth in crop protection in Latin America in the second half, with seed pricing expected to improve in the back half despite near-term commodity cost headwinds. The company is incorporating a $40 million headwind from higher oil prices.

Good report. The company beat and showed some forward improvement, with a few meaningful caveats.

What Corteva, Inc. Does

Corteva, Inc. is a leading agricultural company operating in the seed and crop protection sectors. It develops advanced agricultural products aimed at improving crop yields and resistance to various environmental challenges. Given the volatility in agricultural markets, how well Corteva navigates these challenges will be crucial for its stock performance and analyst ratings.

What to Watch at Corteva, Inc.

As Corteva approaches its next earnings report on November 3, investors will be keen to see how the company addresses its revenue challenges and what guidance it provides for future growth. The mixed sentiments from analysts suggest that the market will be closely monitoring the company's performance and any changes in Wall Street's outlook.